Overview
- On May 28, 2026, SciSparc announced that its majority-owned subsidiary NeuroThera received conditional regulatory approval from the TSX Venture Exchange to acquire roughly 54% of CliniQuantum.
- Under the amended share purchase agreement NeuroThera will issue 56,600,000 common shares in exchange for 56,375 CliniQuantum ordinary shares, an exchange valued at about $9.46 million using NeuroThera’s 20-day VWAP.
- After TSX review the parties amended the SPA to set a $0.05 minimum deemed price for earn-out issuances, establish a floor for future share issuances, require selling-shareholder lock-ups, deposit the consideration shares into escrow via Form 5D, and extend the outside closing date to June 1, 2026 to allow time for an Israeli tax ruling and final TSX acceptance.
- CliniQuantum’s principal asset is an exclusive license from Quantum X Labs and a U.S. provisional patent application for a quantum Markov Chain Monte Carlo method that the company says can help identify patient subgroups and sharpen clinical-trial analytics.
- SciSparc shares jumped about 202% intraday on the announcement and the deal’s completion now depends on the Israeli tax ruling and final TSX acceptance, outcomes that will directly affect SciSparc investors and NeuroThera’s exposure to quantum-enabled trial tools.